TY - JOUR
T1 - Innate Lymphoid Cells
T2 - 10 Years On
AU - Vivier, Eric
AU - Artis, David
AU - Colonna, Marco
AU - Diefenbach, Andreas
AU - Di Santo, James P.
AU - Eberl, Gérard
AU - Koyasu, Shigeo
AU - Locksley, Richard M.
AU - McKenzie, Andrew N.J.
AU - Mebius, Reina E.
AU - Powrie, Fiona
AU - Spits, Hergen
N1 - Funding Information:
Research in the Artis lab is supported by the NIH, the Crohn's and Colitis Foundation , the Burroughs Wellcome Fund , the Cure for IBD , and the Jill Roberts Institute . M.C. is supported by the US NIH ( UO1 AI095542 , RO1 DE025884 , and RO1 DK103039 ).The Diefenbach laboratory is supported by the European Research Council (ERC) ( 311377 - NUTRIMMUNE), the Priority Program 1937 “Innate Lymphoid Cells” of the Deutsche Forschungsgemeinschaft (DFG) , the Einstein Foundation Berlin , and the Berlin Institute of Health . The Eberl lab is supported by grants from ANR, FRM, CCFA, Rainin Foundation and the Institut Pasteur. Research in the Koyasu laboratory is supported by a Grant-in-Aid for Scientific Research (A) ( 16H02631 ). Research in the Locksley laboratory is supported by the HHMI , the NIH , and the SABRE Center at UCSF . Research in the McKenzie laboratory is supported by funding from the MRC ( U105178805 ) and the Wellcome Trust ( 100963/Z/13/Z ). The Di Santo laboratory receives grants from the Institut Pasteur , Inserm , the Agence Nationale de la Recherche , the Ligue Nationale contre le Cancer , and the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program ( 695467 - ILC_REACTIVITY). The Spits lab is supported by an advanced ERC grant ( 341038 -AsthmaVir). Research in the Vivier laboratory is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program ( 694502 -TILC), the Agence Nationale de la Recherche; Equipe Labellisée “La Ligue,” Ligue Nationale contre le Cancer , MSDAvenir , and Innate Pharma and institutional grants to the CIML ( INSERM , CNRS , and Aix-Marseille University ) and Marseille Immunopôle .
Funding Information:
Research in the Artis lab is supported by the NIH, the Crohn's and Colitis Foundation, the Burroughs Wellcome Fund, the Cure for IBD, and the Jill Roberts Institute. M.C. is supported by the US NIH (UO1 AI095542, RO1 DE025884, and RO1 DK103039).The Diefenbach laboratory is supported by the European Research Council (ERC) (311377 - NUTRIMMUNE), the Priority Program 1937 “Innate Lymphoid Cells” of the Deutsche Forschungsgemeinschaft (DFG), the Einstein Foundation Berlin, and the Berlin Institute of Health. The Eberl lab is supported by grants from ANR, FRM, CCFA, Rainin Foundation and the Institut Pasteur. Research in the Koyasu laboratory is supported by a Grant-in-Aid for Scientific Research (A) (16H02631). Research in the Locksley laboratory is supported by the HHMI, the NIH, and the SABRE Center at UCSF. Research in the McKenzie laboratory is supported by funding from the MRC (U105178805) and the Wellcome Trust (100963/Z/13/Z). The Di Santo laboratory receives grants from the Institut Pasteur, Inserm, the Agence Nationale de la Recherche, the Ligue Nationale contre le Cancer, and the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Program (695467 - ILC_REACTIVITY). The Spits lab is supported by an advanced ERC grant (341038-AsthmaVir). Research in the Vivier laboratory is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Program (694502-TILC), the Agence Nationale de la Recherche; Equipe Labellisée “La Ligue,” Ligue Nationale contre le Cancer, MSDAvenir, and Innate Pharma and institutional grants to the CIML (INSERM, CNRS, and Aix-Marseille University) and Marseille Immunopôle.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/8/23
Y1 - 2018/8/23
N2 - Innate lymphoid cells (ILCs) are lymphocytes that do not express the type of diversified antigen receptors expressed on T cells and B cells. ILCs are largely tissue-resident cells and are deeply integrated into the fabric of tissues. The discovery and investigation of ILCs over the past decade has changed our perception of immune regulation and how the immune system contributes to the maintenance of tissue homeostasis. We now know that cytokine-producing ILCs contribute to multiple immune pathways by, for example, sustaining appropriate immune responses to commensals and pathogens at mucosal barriers, potentiating adaptive immunity, and regulating tissue inflammation. Critically, the biology of ILCs also extends beyond classical immunology to metabolic homeostasis, tissue remodeling, and dialog with the nervous system. The last 10 years have also contributed to our greater understanding of the transcriptional networks that regulate lymphocyte commitment and delineation. This, in conjunction with the recent advances in our understanding of the influence of local tissue microenvironments on the plasticity and function of ILCs, has led to a re-evaluation of their existing categorization. In this review, we distill the advances in ILC biology over the past decade to refine the nomenclature of ILCs and highlight the importance of ILCs in tissue homeostasis, morphogenesis, metabolism, repair, and regeneration. Since the discovery of innate lymphoid cells a decade ago, studies in this field have drastically expanded our understanding of the role of the immune system in the maintenance of homeostasis. This Review explores the immune functions of these cells and their connection to metabolism, tissue repair, and the nervous system.
AB - Innate lymphoid cells (ILCs) are lymphocytes that do not express the type of diversified antigen receptors expressed on T cells and B cells. ILCs are largely tissue-resident cells and are deeply integrated into the fabric of tissues. The discovery and investigation of ILCs over the past decade has changed our perception of immune regulation and how the immune system contributes to the maintenance of tissue homeostasis. We now know that cytokine-producing ILCs contribute to multiple immune pathways by, for example, sustaining appropriate immune responses to commensals and pathogens at mucosal barriers, potentiating adaptive immunity, and regulating tissue inflammation. Critically, the biology of ILCs also extends beyond classical immunology to metabolic homeostasis, tissue remodeling, and dialog with the nervous system. The last 10 years have also contributed to our greater understanding of the transcriptional networks that regulate lymphocyte commitment and delineation. This, in conjunction with the recent advances in our understanding of the influence of local tissue microenvironments on the plasticity and function of ILCs, has led to a re-evaluation of their existing categorization. In this review, we distill the advances in ILC biology over the past decade to refine the nomenclature of ILCs and highlight the importance of ILCs in tissue homeostasis, morphogenesis, metabolism, repair, and regeneration. Since the discovery of innate lymphoid cells a decade ago, studies in this field have drastically expanded our understanding of the role of the immune system in the maintenance of homeostasis. This Review explores the immune functions of these cells and their connection to metabolism, tissue repair, and the nervous system.
KW - immunity
KW - innate lymphoid cells
KW - metabolism
KW - neuro-immunology
KW - plasticity
KW - tissue remodeling
UR - http://www.scopus.com/inward/record.url?scp=85050861774&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2018.07.017
DO - 10.1016/j.cell.2018.07.017
M3 - Review article
C2 - 30142344
AN - SCOPUS:85050861774
SN - 0092-8674
VL - 174
SP - 1054
EP - 1066
JO - Cell
JF - Cell
IS - 5
ER -